Irem Eldem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Irem Eldem has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey J. Bednarski
Washington University in St. Louis, Saint Louis, Missouri, United States
2 shared publications - Aditya Raghunathan
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
1 shared publication - Alexa Dickson
Department of Pathology and Immunology Washington University School of Medicine St. Louis Missouri USA
1 shared publication Alysa Poulin
Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada
1 shared publication- Amanda Bell Grimes
Texas Children's Cancer and Hematology Center Texas Children's Hospital Houston Texas USA
1 shared publication Amy A. Swanson
Division of Anatomic Pathology, Mayo Clinic Rochester, Rochester, MN
1 shared publication
Latest Publications
- 12 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70762
Pseudoexon Activation as a Novel Molecular Mechanism for Chediak–Higashi Syndrome
Chediak–Higashi syndrome (CHS) is a hereditary predisposition to hemophagocytic lymphohistiocytosis. We report an adolescent who presented with bicytopenia and progressed to an accelerated phase due to CHS. Neutrophils demonstrated impaired NETosis. Pseudoexon activation in the LYST gene was identified as the underlying molecular mechanism.
- 12 October 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70762
Pseudoexon Activation as a Novel Molecular Mechanism for Chediak–Higashi Syndrome
Chediak–Higashi syndrome (CHS) is a hereditary predisposition to hemophagocytic lymphohistiocytosis. We report an adolescent who presented with bicytopenia and progressed to an accelerated phase due to CHS. Neutrophils demonstrated impaired NETosis. Pseudoexon activation in the LYST gene was identified as the underlying molecular mechanism.
- Open Access
- 17 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 82.e1-82.e8
Excellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia
- 17 September 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 82.e1-82.e8
Open AccessExcellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia
- Open Access
- 24 June 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (10) , 2681-2691
Deletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice
- 24 June 2024
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 22 (10) , 2681-2691
Open AccessDeletion of tissue factor pathway inhibitor isoform beta or gamma, but not alpha, improves clotting in hemophilic mice
- 11 May 2023
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (4) , 443-447
Red blood cell distribution width as a potential inflammatory marker in pediatric osteomyelitis
Red cell distribution width (RDW) has been used in the differential diagnosis of anemia and revealed to be a potential marker of inflammation.We conducted a retrospective study of acute-phase react...
- 11 May 2023
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 36 (4) , 443-447
Red blood cell distribution width as a potential inflammatory marker in pediatric osteomyelitis
Red cell distribution width (RDW) has been used in the differential diagnosis of anemia and revealed to be a potential marker of inflammation.We conducted a retrospective study of acute-phase react...
- Top Cited PapersOpen Access
- 13 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (2) , 256-280
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.
- 13 January 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (2) , 256-280
Top Cited PapersOpen AccessALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
ALK-positive histiocytosis is a rare subtype of histiocytic neoplasm first described in 2008 in 3 infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-positive histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-positive histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (7 and 12 from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one-third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and often conferred strong expression of phosphorylated extracellular signal-regulated kinase, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, whereas CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK, and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, 10 with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-positive histiocytosis and provides guidance for the clinical management of this emerging histiocytic entity.